JP2010511641A5 - - Google Patents

Download PDF

Info

Publication number
JP2010511641A5
JP2010511641A5 JP2009539631A JP2009539631A JP2010511641A5 JP 2010511641 A5 JP2010511641 A5 JP 2010511641A5 JP 2009539631 A JP2009539631 A JP 2009539631A JP 2009539631 A JP2009539631 A JP 2009539631A JP 2010511641 A5 JP2010511641 A5 JP 2010511641A5
Authority
JP
Japan
Prior art keywords
alkylene
alkyl
phenyl
substituted
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009539631A
Other languages
English (en)
Japanese (ja)
Other versions
JP5396279B2 (ja
JP2010511641A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2007/010101 external-priority patent/WO2008067909A2/de
Publication of JP2010511641A publication Critical patent/JP2010511641A/ja
Publication of JP2010511641A5 publication Critical patent/JP2010511641A5/ja
Application granted granted Critical
Publication of JP5396279B2 publication Critical patent/JP5396279B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009539631A 2006-12-06 2007-11-22 ＴＡＦＩａ阻害剤としての尿素及びスルファミド誘導体 Expired - Fee Related JP5396279B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102006057413 2006-12-06
DE102006057413.3 2006-12-06
PCT/EP2007/010101 WO2008067909A2 (de) 2006-12-06 2007-11-22 Harnstoff- und sulfamidderivate als inhibitoren von tafia

Publications (3)

Publication Number Publication Date
JP2010511641A JP2010511641A (ja) 2010-04-15
JP2010511641A5 true JP2010511641A5 (https=) 2010-12-16
JP5396279B2 JP5396279B2 (ja) 2014-01-22

Family

ID=39384480

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009539631A Expired - Fee Related JP5396279B2 (ja) 2006-12-06 2007-11-22 ＴＡＦＩａ阻害剤としての尿素及びスルファミド誘導体

Country Status (27)

Country Link
US (1) US8389764B2 (https=)
EP (1) EP2104497B1 (https=)
JP (1) JP5396279B2 (https=)
KR (1) KR20090087044A (https=)
CN (1) CN101553219B (https=)
AR (1) AR064119A1 (https=)
AU (1) AU2007327959B2 (https=)
BR (1) BRPI0720241A2 (https=)
CA (1) CA2671861C (https=)
CL (1) CL2007003494A1 (https=)
CO (1) CO6180422A2 (https=)
CY (1) CY1116384T1 (https=)
DK (1) DK2104497T3 (https=)
ES (1) ES2537093T3 (https=)
HR (1) HRP20150514T1 (https=)
MA (1) MA30968B1 (https=)
MX (1) MX2009005516A (https=)
NO (1) NO20092246L (https=)
NZ (1) NZ577312A (https=)
PE (1) PE20081349A1 (https=)
PL (1) PL2104497T3 (https=)
PT (1) PT2104497E (https=)
RU (1) RU2459619C2 (https=)
SI (1) SI2104497T1 (https=)
TW (1) TWI399203B (https=)
WO (1) WO2008067909A2 (https=)
ZA (1) ZA200903040B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2300462T1 (sl) 2008-06-06 2014-09-30 Sanofi Makrociklični sečninski in sulfamidni derivati kot inhibitorji za TAFIa
EA018502B1 (ru) 2008-06-23 2013-08-30 Астразенека Аб Новые гетероциклические карбоксамиды и фармацевтические композиции, содержащие их
US8354444B2 (en) 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides
NZ592764A (en) * 2008-10-29 2012-08-31 Taisho Pharmaceutical Co Ltd Compound having tafia inhibitory activity
CA2914533A1 (en) * 2013-06-10 2014-12-18 Sanofi Macrocyclic urea derivatives as inhibitors of tafia, their preparation and their use as pharmaceuticals
CN104529859B (zh) * 2015-01-13 2016-08-17 佛山市赛维斯医药科技有限公司 含苯胺和二烯氟代金刚烷结构的化合物、其制备方法和用途
RU2687254C1 (ru) * 2018-10-03 2019-05-08 Федеральное государственное бюджетное учреждение науки Новосибирский институт органической химии им. Н.Н. Ворожцова Сибирского отделения Российской академии наук (НИОХ СО РАН) N-гетероциклические производные борниламина в качестве ингибиторов ортопоксвирусов

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU667995B2 (en) * 1993-02-15 1996-04-18 Bayer Aktiengesellschaft New pseudopeptides having an antiviral action
TW394760B (en) * 1993-09-07 2000-06-21 Hoffmann La Roche Novel Carboxamides, process for their preparation and pharmaceutical composition containing the same
CA2298601A1 (en) * 1997-08-28 1999-03-11 Pharmacia & Upjohn Company Inhibitors of protein tyrosine phosphatase
US6482921B1 (en) * 1999-01-28 2002-11-19 Essential Therapeutics, Inc. Uridyl peptide antibiotic (UPA) derivatives, their synthesis and use
WO2000056725A1 (en) * 1999-03-19 2000-09-28 Du Pont Pharmaceuticals Company N-adamant-1-yl-n'-[4-chlorobenzothiazol-2-yl] urea useful in the treatment of inflammation and as an anticancer radiosensitizing agent
US6359129B1 (en) * 2000-08-15 2002-03-19 University Of Kansas Amino acid-derived, 7-membered cyclic sulfamides and methods of synthesizing the same
PL361054A1 (en) * 2000-08-17 2004-09-20 Pfizer Inc. Substituted imidazoles as tafia inhibitors
DE102004020186A1 (de) 2004-04-22 2005-11-17 Aventis Pharma Deutschland Gmbh Heterocyclylessigsäuren als Inhibitoren von TAFla
EP1817041A2 (en) * 2004-10-05 2007-08-15 Bayer Schering Pharma Aktiengesellschaft Tafi inhibitors and their use to treat pulmonary fibrosis

Similar Documents

Publication Publication Date Title
JP2010511641A5 (https=)
ES2287782T3 (es) Derivados de n-(heteroaril(piperidin-2-il)metil)benzamida, su preparacion y su aplicacion en terapeutica.
CA2339621C (en) 2-substituted-1-piperidyl benzimidazole compounds as orl1-receptor agonists
AU2004281217B2 (en) Use of tricyclic compounds as glycine transport inhibitors
JP6419155B2 (ja) Ｎ−フェニル−カルボキサミド誘導体およびｂ型肝炎を治療するための医薬品としてのその使用
TW201031654A (en) Inhibitors of HCV NS5A
CN109651342A (zh) 丙型肝炎病毒复制的抑制剂
BR112019012589B1 (pt) Compostos e composição farmacêutica para uso no tratamento de câncer por meio da inibição de atividade de arginase e processo para a produção de composto
TW201033197A (en) Inhibitors of HCV NS5A
TW201138770A (en) Viral polymerase inhibitors
BRPI0518424B1 (pt) derivados de 2,4 (4,6) pirimidina, composição farmacêutica que os compreende, intermediários e uso dos mesmos
TWI666020B (zh) 固體分散製劑
WO2022053696A1 (en) Novel safrylamine derivatives having prodrug properties
EA020949B1 (ru) Замещенные азолы, противовирусный активный компонент, фармацевтическая композиция, способ получения и применения
JP2022537905A (ja) ヒストン脱アセチル化酵素６阻害剤としての１，３，４－オキサジアゾール誘導体化合物、およびそれを含む薬剤学的組成物
CN110143925B (zh) 乙内酰脲异羟肟酸类组蛋白去乙酰化酶6亚型选择性抑制剂及制备方法和应用
JP2011521981A5 (https=)
KR20240128987A (ko) Flt3의 억제제로서의 피라진 화합물
JP5782438B2 (ja) アミド化合物の結晶
RU2436786C1 (ru) Замещенные индолы, противовирусный активный компонент, способ получения и применения
WO2023027966A1 (en) Pyrazine compounds as irreversible inhibitors of flt3
HRP20150514T1 (hr) DERIVATI SULFAMIDA KAO INHIBITORI TAFIa
JP2008543957A5 (https=)
HRP20100150T1 (hr) N-(arilalkil)-1h-pirolopiridin-2-karboksamidni derivati, njihovo dobivanje i upotreba
JP2009511516A5 (https=)